PFE - Alnylam picked for positive catalyst watch at Citi on amyloidosis therapy.
2023-09-05 13:54:34 ET
More on Alnylam
- Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals
- Historical earnings data for Alnylam Pharmaceuticals
- Financial information for Alnylam Pharmaceuticals
- Alnylam: Unlimited Promise Or Unlimited Losses?
- Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Alnylam Pharmaceuticals, Inc. ( ALNY ) Q2 2023 Earnings Call Transcript
- Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline
- Alnylam appealing patent ruling in case against Moderna
- Roche, Alnylam in pact for blood pressure candidate
- Alnylam to face FDA AdCom meeting on amyloidosis drug
For further details see:
Alnylam picked for positive catalyst watch at Citi on amyloidosis therapy.